Tumor Regression Grading After Preoperative Chemoradiotherapy for Locally Advanced Rectal Carcinoma Revisited: Updated Results of the CAO/ARO/AIO-94 Trial
about
Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical TrialsWatch and wait approach to rectal cancer: A reviewSystematic review and meta-analysis of preoperative chemoradiotherapy with or without oxaliplatin in locally advanced rectal cancer.The Prognostic Value of Tyrosine Kinase SRC Expression in Locally Advanced Rectal Cancer.Increased number of negative lymph nodes is associated with improved cancer specific survival in pathological IIIB and IIIC rectal cancer treated with preoperative radiotherapy.Tumor regression grades: potential outcome predictor of locally advanced rectal adenocarcinoma after preoperative radiotherapy.Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional studyTumor Volume Reduction Rate Predicts Pathologic Tumor Response of Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemotherapy alone: Results from a Prospective TrialTumor volume reduction rate is superior to RECIST for predicting the pathological response of rectal cancer treated with neoadjuvant chemoradiation: Results from a prospective studyImpact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy.Reduced toxicity in the treatment of locally advanced rectal cancer: a comparison of volumetric modulated arc therapy and 3D conformal radiotherapy.Prognostic Effect of Pretreatment Serum Carcinoembryonic Antigen Level: A Useful Tool for Prediction of Distant Metastasis in Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancerLow stromal Foxp3+ regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer.Phospho-ERK1/2 levels in cancer cell nuclei predict responsiveness to radiochemotherapy of rectal adenocarcinoma.Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trialNew tumor regression grade for rectal cancer after neoadjuvant therapy and radical surgery.Short-term Outcomes of an Extralevator Abdominoperineal Resection in the Prone Position Compared With a Conventional Abdominoperineal Resection for Advanced Low Rectal Cancer: The Early Experience at a Single Institution.Nomogram basing pre-treatment parameters predicting early response for locally advanced rectal cancer with neoadjuvant chemotherapy alone: a subgroup efficacy analysis of FOWARC studyPrognostic Value of MicroRNAs in Preoperative Treated Rectal Cancer.Outcomes of neoadjuvant chemoradiotherapy in Japanese locally advanced rectal carcinoma patients.Preoperative chemoradiation for locally advanced rectal cancer: comparison of three radiation dose and fractionation schedules.Lymph nodes regression grade is a predictive marker for rectal cancer after neoadjuvant therapy and radical surgery.Pathological Assessment of the AJCC Tumor Regression Grading System After Preoperative Chemoradiotherapy for Chinese Locally Advanced Rectal Cancer.Defining response to radiotherapy in rectal cancer using magnetic resonance imaging and histopathological scales.Correlation between tumor regression grade and rectal volume in neoadjuvant concurrent chemoradiotherapy for rectal cancer.Preoperative chemoradiotherapy followed by local excision in clinical T2N0 rectal cancer.Long-Term Outcome of Rectal Cancer With Clinically (EUS/MRI) Metastatic Mesorectal Lymph Nodes Treated by Neoadjuvant Chemoradiation: Role of Organ Preservation Strategies in Relation to Pathologic ResponseA Retrospective Analysis on Two-week Short-course Pre-operative Radiotherapy in Elderly Patients with Resectable Locally Advanced Rectal Cancer.Do pathological variables have prognostic significance in rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and surgery?Novel lymph node ratio predicts prognosis of colorectal cancer patients after radical surgery when tumor deposits are counted as positive lymph nodes: a retrospective multicenter studyIs the pathological regression level of metastatic lymph nodes associated with oncologic outcomes following preoperative chemoradiotherapy in rectal cancer?Chemoradiotherapy and concurrent radiofrequency thermal therapy to treat primary rectal cancer and prediction of treatment responses.Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer.The Pretreatment Systemic Inflammatory Response is an Important Determinant of Poor Pathologic Response for Patients Undergoing Neoadjuvant Therapy for Rectal CancerTumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response.Optimal therapy for resectable rectal cancer.Intravoxel Incoherent Motion-derived Histogram Metrics for Assessment of Response after Combined Chemotherapy and Radiation Therapy in Rectal Cancer: Initial Experience and Comparison between Single-Section and Volumetric AnalysesHypoxia-Associated Marker CA IX Does Not Predict the Response of Locally Advanced Rectal Cancers to Neoadjuvant Chemoradiotherapy.
P2860
Q26796253-E8205471-27D3-43CC-8958-2F587E36E45BQ28080688-97D27DC9-5B12-4421-A362-CAE8E5D5AAA3Q30235044-80562146-DD88-4E04-A439-C783FA2F44FFQ33776733-CF75F788-8AAB-4496-8FED-ADB4991E77BCQ35068085-14B1B46A-90E2-42EB-9DE8-46B7C8DBC84CQ35069485-14A1DF47-3DFA-4E10-98E3-B64C7145BF34Q35269337-DA20EFCD-6195-4127-8E63-0DE77696A2FAQ35433475-3828DE5D-2C57-4F83-8C82-BB8651A2113EQ35739533-071042BE-62A7-490C-A8BF-1D12103BB177Q35758067-1ED9F01B-DFBA-4344-BD8E-3B627FC9454DQ35779456-54FE1723-4D0A-4B28-B3CE-8771E6B21A0FQ35815373-7AEC0739-FF00-4673-9E6C-ADCA5C7A53ABQ36194714-60A5CE01-4F88-48B9-9F48-AEB7EF63B650Q36235746-C82004F4-B98F-41F5-8B97-8BF7863A7676Q36432125-BE0EFCC2-3C6D-4D15-BD49-868051226E01Q36544089-FFA29FFA-B499-4927-93D7-CFE1E613119AQ36557606-C7355B35-6C1D-44AF-B232-6596D678905FQ36561726-D901B6D4-3F1F-40F6-B99C-23B3788BF41EQ36665929-9A048A6E-0B38-4FD2-B7F5-C2FF541C3D25Q36782675-5C7C931D-345C-44A8-905E-BD8557AE4562Q36847230-54E33A36-BDAF-4CA9-ABC3-6DADAB68DE6DQ36853674-1891C313-8E62-40DC-A84C-F3719C7DC547Q37079063-3D3ECA30-5ECE-4B98-9872-598F3679E1ECQ37086177-75FBA45B-BF94-4B23-A330-28C30F04FCFDQ37204825-9D5A341D-B04B-4F5D-9E36-700B5C70D5CDQ37322482-0A6B7A2A-7F0F-4ED5-95B8-2B5370E6E0F7Q37343466-B9977199-A1C2-437C-9926-4CEDCE0E4509Q37343477-FFD9C353-78AC-4CAE-8857-0D9296EB47E8Q37385667-43053AAF-7745-4A1D-BDFF-9F562282E973Q37439354-E3A33278-AA61-4039-883B-CEA1BA042690Q37672227-99A46033-902D-474C-ADF2-9FAAC7C6FCD3Q37687482-589229B3-930D-4F20-8D89-AA4B02FEA4DEQ37705840-6169F6A0-916D-4D3C-B290-D498073DC809Q37707552-721EE2B8-C3C3-45CB-9B55-7EECC019D567Q37729169-B6ED7D1A-4D5F-450C-8960-E0F6F836F30CQ37730979-569225FB-A292-40E3-B466-5AE316D5FCC5Q37746144-257E226E-04FD-4A34-9F8D-C9D8F704D871Q38664897-A1559337-40E9-410B-A413-CE929005D6D2Q38751651-91624238-C527-40CE-9B7A-8B227CB27A9DQ40345504-99420C8D-D645-4D27-8329-45ADCB70084E
P2860
Tumor Regression Grading After Preoperative Chemoradiotherapy for Locally Advanced Rectal Carcinoma Revisited: Updated Results of the CAO/ARO/AIO-94 Trial
description
im Mai 2014 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2014
@uk
name
Tumor Regression Grading After ...... ts of the CAO/ARO/AIO-94 Trial
@en
Tumor Regression Grading After ...... ts of the CAO/ARO/AIO-94 Trial
@nl
type
label
Tumor Regression Grading After ...... ts of the CAO/ARO/AIO-94 Trial
@en
Tumor Regression Grading After ...... ts of the CAO/ARO/AIO-94 Trial
@nl
prefLabel
Tumor Regression Grading After ...... ts of the CAO/ARO/AIO-94 Trial
@en
Tumor Regression Grading After ...... ts of the CAO/ARO/AIO-94 Trial
@nl
P2093
P356
P1476
Tumor Regression Grading After ...... ts of the CAO/ARO/AIO-94 Trial
@en
P2093
Christian Wittekind
Clemens Hess
Emmanouil Fokas
Hans-Rudolf Raab
Heinz Becker
Michael Ghadimi
Rolf Sauer
Susanne Merkel
Tim Beissbarth
P304
P356
10.1200/JCO.2013.54.3769
P407
P577
2014-05-20T00:00:00Z